Bortezomib

• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended
  2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended
  2023-508212-38-00 Phase II 3 countries North Estonia Medical Centre Foundation
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended
  2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
• Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Ended
  2022-500453-16-00 Phase II 1 country University Medical Centre Schleswig-Holstein
• Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, … Ended
  2024-518658-18-00 Phase II 1 country Medical University Of Warsaw
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended
  2024-514016-26-00 Phase II 1 country Fundacion Pethema
• Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma Ended
  2024-516250-22-00 Phase II 1 country Ceska Myelomova Skupina z.s.
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended
  2023-503444-13-00 Phase III 13 countries Janssen - Cilag International
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended
  2023-509859-13-00 Phase III 13 countries Celgene Corp.
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended
  2024-517008-12-00 Phase III 1 country Fundacion PETHEMA
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended
  2024-510800-35-00 Phase III 16 countries Celgene Corp.
• Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended
  2024-512749-18-00 Phase II 2 countries Cancer Trials Ireland
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended
  2024-515037-15-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended
  2023-503441-55-00 Phase II 10 countries Janssen - Cilag International
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended
  2023-505850-16-00 Phase III 16 countries Janssen - Cilag International
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• The REST (Replacing Steroids in the transplant ineligible) study. Ended
  2023-510194-34-00 Phase II 2 countries Oslo University Hospital HF
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Ended
  2024-517215-67-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended
  2023-506877-37-00 Phase III 7 countries Glaxosmithkline Research & Development Limited
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended
  2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended
  2023-510537-28-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
• Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended
  2024-514963-24-00 Phase II 2 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended
  2023-506587-13-00 Phase II 5 countries Janssen - Cilag International
• Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of dr… Ended
  2024-518473-34-00 Phase III 3 countries Polish Myeloma Consortium

Showing 25–48 of 71 trials